A New Era of Oral Anticoagulation in Atrial Fibrillation: Implications in Clinical Practice

References

• . Go AS, Hylek EM, Phillips KA, . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
   PubMed Web of Science ®Google Scholar
• . Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476–484
   PubMed Web of Science ®Google Scholar
• . Healey JS, Connolly SJ, Gold MR, ; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–129
   PubMed Web of Science ®Google Scholar
• . Wessler S, Gitel SN. Pharmacology of heparin and warfarin. J Am Coll Cardiol. 1986;8(6 suppl B):10B–20B
   Google Scholar
• . Holbrook AM, Pereira JA, Labiris R, . Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106
   PubMed Web of Science ®Google Scholar
• . Katsnelson M, Sacco RL, Moscucci M. Progress for stroke prevention with atrial fibrillation: emergence of alternative OACs. Stroke. 2012;43(4):1179–1185
   Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376–381
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Camm AJ, Kirchhof P, Lip GY, ; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429
   PubMed Web of Science ®Google Scholar
• . Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124(2):111–114
   Google Scholar
• . Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298–2307
   PubMed Web of Science ®Google Scholar
• . Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new OACs (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–589
   PubMed Web of Science ®Google Scholar
• . Oldgren J, Alings M, Darius H, ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155(10):660–667
   PubMed Web of Science ®Google Scholar
• . Diener HC, Connolly SJ, Ezekowitz MD, ; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–1163
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Yusuf S, Ezekowitz MD, ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983
   PubMed Web of Science ®Google Scholar
• . Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new OAC drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738–746
   PubMed Web of Science ®Google Scholar
• . Therapeutic Goods Administration. Dabigatran (Pradaxa):risk of bleeding relating to use. http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm. Published November 3, 2011. Accessed July 16, 2012
   Google Scholar
• . US Food and Drug Administration.Pradaxa (dabigatran etexilate mesylate): drug safety communication. Safety review of post-market reports of serious bleeding events. http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm. Published December 7, 2011. Accessed July 16, 2012
   Google Scholar
• . Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407–418
   PubMedGoogle Scholar
• . Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med. 2012;157(1):66–68
   PubMed Web of Science ®Google Scholar
• . Sorensen SV, Kansal AR, Connolly S, . Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908–919
   PubMed Web of Science ®Google Scholar
• . Freeman JV, Zhu RP, Owens DK, . Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11
   PubMed Web of Science ®Google Scholar
• . Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–2570
   PubMed Web of Science ®Google Scholar
• . Cadilhac DA. The economics of atrial fibrillation: a time for review and prioritization. Int J Stroke. 2012;7(6):477–479
   Google Scholar
• . DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811
   PubMed Web of Science ®Google Scholar
• . Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009;15(1):34–44
   PubMed Web of Science ®Google Scholar
• . Phillips KW, Ansell J. The clinical implications of new OACs: will the potential advantages be achieved? Thromb Haemost. 2010;103(1):34–39
   Google Scholar
• . Wann LS, Curtis AB, Ellenbogen KA, ; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123(10):1144–1150
   PubMed Web of Science ®Google Scholar
• . Potpara TS, Lip GY, Apostolakis S. New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart. 2012;98(18):1341–1347
   Google Scholar
• . Skanes AC, Healey JS, Cairns JA, ; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125–136
   PubMed Web of Science ®Google Scholar
• . Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009;35(5):515–524
   Google Scholar
• . Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e44S–e88S
   PubMed Web of Science ®Google Scholar
• . van Ryn J, Stangier J, Haertter S, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127
   PubMed Web of Science ®Google Scholar
• . Lip GY, Huber K, Andreotti F, ; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103(1):13–28
   PubMedGoogle Scholar
• . Mega JL, Braunwald E, Wiviott SD, ; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19
   PubMed Web of Science ®Google Scholar
• . Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23(3):264–268
   PubMed Web of Science ®Google Scholar
• . Lakkireddy D, Reddy YM, Di Biase L, . Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–1174
   PubMed Web of Science ®Google Scholar
• . Nagarakanti R, Ezekowitz MD, Oldgren J, . Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–136
   PubMed Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. Explore the Efficacy and Safety of Once-Daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion. NCT01674647. http://clinicaltrials.gov/show/NCT01674647. Accessed July 16, 2012
   Google Scholar
• . Healey JS, Eikelboom J, Douketis J, ; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY randomized trial. Circulation. 2012;126(3):343–348
   PubMed Web of Science ®Google Scholar
• . Spyropoulos AC. Pro: “Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery”. Thromb Haemost. 2012;108(2):213–216
   PubMed Web of Science ®Google Scholar
• . Pengo V, Crippa L, Falanga A, ; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106(5):868–876
   PubMed Web of Science ®Google Scholar
• . Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011;105(4):574–548
   PubMed Web of Science ®Google Scholar
• . Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104(1):49–60
   PubMed Web of Science ®Google Scholar